KR20230042594A - B 세포 악성종양의 치료 - Google Patents

B 세포 악성종양의 치료 Download PDF

Info

Publication number
KR20230042594A
KR20230042594A KR1020237007141A KR20237007141A KR20230042594A KR 20230042594 A KR20230042594 A KR 20230042594A KR 1020237007141 A KR1020237007141 A KR 1020237007141A KR 20237007141 A KR20237007141 A KR 20237007141A KR 20230042594 A KR20230042594 A KR 20230042594A
Authority
KR
South Korea
Prior art keywords
binding fragment
baffr antibody
baffr
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237007141A
Other languages
English (en)
Korean (ko)
Inventor
나디아 하수나
안웨샤 차우더리
소메시 초우더리
장희 우
니콜 안주 푼자비 쿤다말
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20230042594A publication Critical patent/KR20230042594A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Seeds, Soups, And Other Foods (AREA)
KR1020237007141A 2020-08-04 2021-08-02 B 세포 악성종양의 치료 Pending KR20230042594A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063060786P 2020-08-04 2020-08-04
US63/060,786 2020-08-04
US202063114363P 2020-11-16 2020-11-16
US63/114,363 2020-11-16
US202163147507P 2021-02-09 2021-02-09
US63/147,507 2021-02-09
PCT/US2021/044113 WO2022031567A1 (en) 2020-08-04 2021-08-02 Treatment of b cell malignancies

Publications (1)

Publication Number Publication Date
KR20230042594A true KR20230042594A (ko) 2023-03-28

Family

ID=77448106

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237007141A Pending KR20230042594A (ko) 2020-08-04 2021-08-02 B 세포 악성종양의 치료

Country Status (10)

Country Link
US (1) US20230279132A1 (cg-RX-API-DMAC7.html)
EP (1) EP4192869A1 (cg-RX-API-DMAC7.html)
JP (1) JP7834711B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230042594A (cg-RX-API-DMAC7.html)
CN (1) CN116133687A (cg-RX-API-DMAC7.html)
AU (1) AU2021320129B2 (cg-RX-API-DMAC7.html)
CA (1) CA3190678A1 (cg-RX-API-DMAC7.html)
IL (1) IL300086A (cg-RX-API-DMAC7.html)
TW (1) TW202221033A (cg-RX-API-DMAC7.html)
WO (1) WO2022031567A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
AU2009272771B2 (en) 2008-07-17 2012-09-20 Novartis Ag Compositions and methods of use for therapeutic antibodies
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US11136405B2 (en) * 2016-06-06 2021-10-05 Board Of Regents, The Unviersity Of Texas System BAFF-R antibodies and uses thereof
CA3160207A1 (en) * 2019-11-06 2021-05-14 Novartis Ag Treatment for sjogren's syndrome

Also Published As

Publication number Publication date
JP2023536596A (ja) 2023-08-28
AU2021320129B2 (en) 2025-12-18
JP7834711B2 (ja) 2026-03-24
WO2022031567A1 (en) 2022-02-10
US20230279132A1 (en) 2023-09-07
AU2021320129A1 (en) 2023-03-16
CA3190678A1 (en) 2022-02-10
TW202221033A (zh) 2022-06-01
CN116133687A (zh) 2023-05-16
EP4192869A1 (en) 2023-06-14
IL300086A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
KR102776925B1 (ko) Flt3l-fc 융합 단백질 및 사용 방법
JP7431394B2 (ja) Her2、nkg2dおよびcd16に結合する多重特異性結合タンパク質ならびに使用方法
CN112533944A (zh) 多特异性结合蛋白及其改进
KR20250065936A (ko) 면역 체크포인트 억제제를 사용하여 암을 치료하는 방법
TW201731528A (zh) 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合
TW202340247A (zh) 結合nkg2d、cd16、及5t4之蛋白質
TW202332699A (zh) 靶向5t4之抗體及其用途
CA3193421A1 (en) Lag-3 antagonist therapy for hepatocellular carcinoma
TW202142561A (zh) 抗hpv t細胞受體和工程化細胞
KR20240130705A (ko) Il-7 단백질 및 vegf 길항제의 조합으로 종양을 치료하는 방법
KR20240135661A (ko) 간세포성 암종에 대한 조합 요법
JP2023528630A (ja) エプスタイン-バーウイルスを標的とするtcr-t細胞療法
CN114945409A (zh) 用il-7蛋白和双特异性抗体的组合治疗肿瘤的方法
AU2021320129B2 (en) Treatment of B cell malignancies
AU2021320130B2 (en) Treatment of CLL
TW202508632A (zh) 使用抗pd-1及化學療法治療肺癌
HK40091842A (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
EA045919B1 (ru) СЛИТЫЕ БЕЛКИ FLT3L-Fc И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK40071848B (en) Flt3l-fc fusion proteins and methods of use
HK40071848A (en) Flt3l-fc fusion proteins and methods of use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240711

Comment text: Request for Examination of Application